No Abstract BioWorld International CorrespondentPARIS - Xentech, a contract research start-up specialized in evaluating the efficacy of anticancer therapies, raised seed capital of €600,000 (US$765,000) from Aurinvest Capital 2, indicating that would help it put together a €4 million development plan.